• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

补体替代途径中H因子和I因子在控制液相激活方面的具体作用。

The specific contributions of factor H and factor I in controlling fluid phase activation of the alternative complement pathway.

作者信息

Turner Nancy A, Moake Joel L

机构信息

Department of Bioengineering, Rice University, Houston, TX, USA.

出版信息

Sci Rep. 2025 Mar 29;15(1):10883. doi: 10.1038/s41598-025-95533-6.

DOI:10.1038/s41598-025-95533-6
PMID:40158007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11954907/
Abstract

The immediate defense provided by the alternative complement pathway (AP) is under constant control by fluid phase regulators, factor H (FH) and factor I (FI), to prevent nonessential activation. Removal of either FI or FH from serum results in spontaneous AP activation, although the extent of activation caused by separate removal of each regulator has not been compared. In purified protein reactions with < 25% normal FH levels, additions of 6-100% normal FI levels, did not reduce C3a, Ba or FB cleavage. In reactions with 100% FH: C3a was not generated; Ba and FB cleavage was 3-fold lower; and C3 inactivation increased 2-fold as FI concentrations doubled. In reactions with 100% FI, FH levels ≥ 25% reduced C3a and Ba levels. AP activation levels were also compared in FI-depleted and FH-depleted serum. After magnesium addition to FI-depleted serum, C3a remained unchanged and Ba increased 3-fold, whereas in FH-depleted serum, C3a increased 13-fold and Ba increased 20-fold. Addition of 100% FI protein to FI-depleted serum did not change C3a and Ba, whereas, 100% FH added to FH-depleted serum prevented all activation. We conclude that normal levels of FH are sufficient to compensate for FI deficiencies and prevent unnecessary fluid phase AP activation.

摘要

替代补体途径(AP)提供的即时防御受到液相调节因子H因子(FH)和I因子(FI)的持续控制,以防止不必要的激活。从血清中去除FI或FH都会导致AP自发激活,不过尚未比较单独去除每种调节因子所引起的激活程度。在纯化蛋白反应中,当FH水平低于正常水平的25%时,添加6% - 100%正常水平的FI,并不会减少C3a、Ba或FB的裂解。在100% FH的反应中:不会产生C3a;Ba和FB的裂解降低3倍;随着FI浓度加倍,C3失活增加2倍。在100% FI的反应中,FH水平≥25%可降低C3a和Ba水平。还比较了FI缺失血清和FH缺失血清中的AP激活水平。向FI缺失血清中添加镁后,C3a保持不变,Ba增加3倍,而在FH缺失血清中,C3a增加13倍,Ba增加20倍。向FI缺失血清中添加100%的FI蛋白不会改变C3a和Ba,而向FH缺失血清中添加100%的FH可防止所有激活。我们得出结论,正常水平的FH足以补偿FI缺陷并防止不必要的液相AP激活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/a3d503327978/41598_2025_95533_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/a091021249c4/41598_2025_95533_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/cc2c614b6e49/41598_2025_95533_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/329507d45b9c/41598_2025_95533_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/1c8a6f079317/41598_2025_95533_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/829619518d35/41598_2025_95533_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/a3d503327978/41598_2025_95533_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/a091021249c4/41598_2025_95533_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/cc2c614b6e49/41598_2025_95533_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/329507d45b9c/41598_2025_95533_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/1c8a6f079317/41598_2025_95533_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/829619518d35/41598_2025_95533_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/11954907/a3d503327978/41598_2025_95533_Fig6_HTML.jpg

相似文献

1
The specific contributions of factor H and factor I in controlling fluid phase activation of the alternative complement pathway.补体替代途径中H因子和I因子在控制液相激活方面的具体作用。
Sci Rep. 2025 Mar 29;15(1):10883. doi: 10.1038/s41598-025-95533-6.
2
Heat-inactivated Factor B inhibits alternative pathway fluid-phase activation and convertase formation on endothelial cell-secreted ultra-large von Willebrand factor strings.热灭活因子 B 抑制内皮细胞分泌的超大 von Willebrand 因子串上替代途径液相反响的激活和转化酶形成。
Sci Rep. 2023 Apr 8;13(1):5764. doi: 10.1038/s41598-023-33007-3.
3
Changes in complement alternative pathway components, factor B and factor H during dengue virus infection in the AG129 mouse.登革病毒感染 AG129 小鼠时补体替代途径成分、因子 B 和因子 H 的变化。
J Gen Virol. 2021 Mar;102(3). doi: 10.1099/jgv.0.001547. Epub 2021 Jan 7.
4
Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr⁴⁰²His polymorphism.年龄相关性黄斑变性患者替代途径补体蛋白的血浆水平与补体因子H Tyr⁴⁰²His多态性无关。
Mol Vis. 2012;18:2288-99. Epub 2012 Aug 30.
5
Modulation of complement activation on hemodialysis membranes by immobilized heparin.固定化肝素对血液透析膜上补体激活的调节作用。
J Am Soc Nephrol. 1992 Feb;2(8):1328-37. doi: 10.1681/ASN.V281328.
6
A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.一种导致家族性非典型溶血性尿毒症综合征中 C3 转化酶形成增加的新型 C3 突变。
J Immunol. 2012 Feb 15;188(4):2030-7. doi: 10.4049/jimmunol.1100319. Epub 2012 Jan 16.
7
Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes.血浆补体成分及激活片段:与年龄相关性黄斑变性的基因型和表型的关联
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5818-27. doi: 10.1167/iovs.09-3928. Epub 2009 Aug 6.
8
Dengue Virus Induces Increased Activity of the Complement Alternative Pathway in Infected Cells.登革热病毒诱导感染细胞中补体替代途径的活性增加。
J Virol. 2018 Jun 29;92(14). doi: 10.1128/JVI.00633-18. Print 2018 Jul 15.
9
Liver factor B silencing to cure C3 glomerulopathy: Evidence from a mouse model of complement dysregulation.肝因子 B 沉默治疗补体失调性 C3 肾小球病:来自补体失调小鼠模型的证据。
Mol Immunol. 2023 Sep;161:25-32. doi: 10.1016/j.molimm.2023.07.010. Epub 2023 Jul 21.
10
An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.一种用于治疗 C3 肾小球病的工程补体因子 H 构建体。
J Am Soc Nephrol. 2018 Jun;29(6):1649-1661. doi: 10.1681/ASN.2017091006. Epub 2018 Mar 27.

本文引用的文献

1
Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic.补体因子 I:调控枢纽、免疫病理驱动因子及治疗靶点。
Immunobiology. 2023 Sep;228(5):152410. doi: 10.1016/j.imbio.2023.152410. Epub 2023 Jun 5.
2
Heat-inactivated Factor B inhibits alternative pathway fluid-phase activation and convertase formation on endothelial cell-secreted ultra-large von Willebrand factor strings.热灭活因子 B 抑制内皮细胞分泌的超大 von Willebrand 因子串上替代途径液相反响的激活和转化酶形成。
Sci Rep. 2023 Apr 8;13(1):5764. doi: 10.1038/s41598-023-33007-3.
3
Purified complement C3b triggers phagocytosis and activation of human neutrophils via complement receptor 1.
经纯化的补体 C3b 通过补体受体 1 触发人中性粒细胞的吞噬作用和激活。
Sci Rep. 2023 Jan 6;13(1):274. doi: 10.1038/s41598-022-27279-4.
4
Initiation of the alternative pathway of complement and the history of "tickover".补体替代途径的激活与“持续激活”的历程。
Immunol Rev. 2023 Jan;313(1):64-70. doi: 10.1111/imr.13130. Epub 2022 Sep 11.
5
Complement factor serum and plasma levels measured by a MILLIPLEX Magnetic Bead Panel: A reply.通过MILLIPLEX磁珠板检测的补体因子血清和血浆水平:一则回复。
Scand J Immunol. 2021 Jun;93(6):e13036. doi: 10.1111/sji.13036. Epub 2021 Mar 18.
6
Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis.补体受体及其在白细胞募集和吞噬作用中的作用。
Front Cell Dev Biol. 2021 Feb 11;9:624025. doi: 10.3389/fcell.2021.624025. eCollection 2021.
7
Inherited Kidney Complement Diseases.遗传性肾脏补体疾病。
Clin J Am Soc Nephrol. 2021 Jun;16(6):942-956. doi: 10.2215/CJN.11830720. Epub 2021 Feb 3.
8
Primary pneumococcal peritonitis can be the first presentation of a familial complement factor I deficiency.原发性肺炎球菌性腹膜炎可能是家族性补体因子 I 缺陷的首发表现。
Clin Exp Immunol. 2020 Dec;202(3):379-383. doi: 10.1111/cei.13490. Epub 2020 Jul 24.
9
Is generation of C3(HO) necessary for activation of the alternative pathway in real life?在现实生活中,C3(HO)的产生是否是替代途径激活所必需的?
Mol Immunol. 2019 Oct;114:353-361. doi: 10.1016/j.molimm.2019.07.032. Epub 2019 Aug 22.
10
The story of complement factor I.补体因子 I 的故事。
Immunobiology. 2019 Jul;224(4):511-517. doi: 10.1016/j.imbio.2019.05.003. Epub 2019 May 10.